Aiforia Technologies: Direction continues upward
Aiforia’s H2 was largely in line with our expectations and the company’s sales pipeline is still promising. We still consider the company’s competitive position as good and if Aiforia continues winning customers as expected, the potential will gradually begin to emerge more clearly in revenue. On the other hand, poor growth predictability and elevated financial risks argue for some caution in pricing the potential.
Aiforia Technologies
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures08.03
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 2.4 | 4.3 | 8.1 |
growth-% | 49.32 % | 80.10 % | 88.37 % |
EBIT (adj.) | -12.9 | -11.4 | -10.2 |
EBIT-% (adj.) | -537.07 % | -262.96 % | -125.39 % |
EPS (adj.) | -0.50 | -0.44 | -0.39 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |